Genomic Testing

Technician working with tissue samples

A genomic profile is more than just a test. Our assays provide biomarker information to help match patients to approved targeted therapies, immunotherapies, and clinical trials — giving doctors and patients powerful actionable insights for navigating cancer care.

Uncovering More Options for Each Unique Cancer

Each cancer is unique and each tumor can vary at the molecular level. A single genomic test can reveal alterations in DNA that drive cancer growth to help identify personalized treatment options based on a tumor’s unique genomic profile.

Next-Generation Sequencing (NGS) is used to analyze cancer specimens for all four classes of genomic alterations (base substitutions, insertions and deletions, copy number alterations, and rearrangements) known to be relevant in solid tumors, sarcomas, and hematologic malignancies.

Getting a Foundation Medicine Test

  1. Physician and patient discuss testing options together.
  2. Physician orders the appropriate test.
  3. Physician collects a tissue, blood, or bone marrow sample from patient.
  4. Physician sends sample to the Foundation Medicine laboratory.
  5. Physician receives online and printed results typically within 2 weeks from receipt of sample at Foundation Medicine.
  6. Physician and patient discuss results and potential treatment options.

Compare Foundation Tests

Our Diagnostic Portfolio

  • Foundation Medicine Symbol
  • Indications
  • Sample Type
  • Tumor Mutational Burden (TMB)*
  • Microsatellite instability (MSI)*
  • FoundationOne CDx™
  • All Solid Tumors
  • FFPE
  • Yes
  • Yes
  • Details →
  • FoundationOne®
  • NSCLC, CRC, Melanoma, and other solid tumors
  • FFPE
  • Yes
  • Yes
  • Details →
  • FoundationACT®
  • Lung, GI, Breast, and other solid tumors
  • Peripheral Whole Blood
  • No
  • No
  • Details →
  • FoundationOne®Heme
  • Leukemias, lymphomas, or sarcomas
  • FFPE, Peripheral Whole Blood, Bone Marrow Aspirate
  • Yes
  • Yes
  • Details →

Cancer Immunotherapy Biomarkers

Helping Predict Response with Tumor Mutational Burden

Cancer immunotherapies have the potential to treat cancer by harnessing the power of our own immune systems. But right now, only about 20-40% of people respond to this important class of therapy.1,2 Learn about a quantitative clinical biomarker, tumor mutational burden (TMB), that can help identify patients who may be more likely to benefit from cancer immunotherapies.3

Learn More About TMB

Results & Reporting

Test results are provided directly to physicians in a report that highlights the genomic alterations in a patient’s cancer and includes information to help inform treatment decisions. Everything in the report is supported by up-to-date clinical findings and scientific research. Patients may request a copy of their report by contacting Client Services.

  1. Genomic Alterations
    Information about identified genomic alterations of all types and interpretation of results.
  2. Therapies
    List of available therapies relevant for the genomic alterations identified.
  3. Clinical Trials
    Clinical trials that the patient may be eligible for and guidance for the physician on identifying additional trials in public databases.
  4. Appendix
    Additional information such as the full list of genes assayed, variants of unknown significance, technical information, and references.
Genomic Testing Report

View a Sample FoundationOne CDx™ Report

Track Orders and View Patient Reports Online or On Your Phone

|

Our secure online portal allows physicians to order testing, track orders in progress, and view patient reports when available. Create an account today for online and mobile access.

Sign up today or download the iOS app

Patient Reports and Mobile App

Support Services

A patient with cancer should not have to worry about the affordability of testing. That’s why we offer the FoundationAccess financial assistance program.

Learn More About Our Medicare Compliance Policy

A patient

Financial Assistance Program

Our financial assistance program provides patients with the opportunity for comprehensive genomic profiling, regardless of financial status. We also offer direct support and guidance during each step of the billing process.

Apply for Financial Assistance

A Foundation Medicine employee taking a phone call

Contact Us

We're committed to excellent service. If you have questions or need assistance, our client services team is on-hand to help.

Contact Client Services

Need More Details?

* Tumor Mutational Burden is a validated clinical marker associated with response to immunotherapy.

1 Márquez-Rodas et al. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med. 2015 October;3(18):267.

2 Wolchok et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013 July 11;369(2):122-33.

3 Goodman AM, et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 Nov;16(11):2598-2608.